Multiple Companies Issue Corporate And Clinical Disclosures
Tap title to read story
United States, Multiple companies announced corporate and clinical developments this week, including conversions, leadership changes, financing, trial updates and adoptions. Advanced Flower Capital completed its conversion to a business development company, Casella installed a new CEO, and Corvus scheduled Phase 1 cohort results; several firms declared January distributions; Archrock proposed a $500 million senior note offering; Riot and TOMI released operational updates; Instil Bio discontinued a clinical program and terminated a license; Calumet provided preliminary fiscal results; Mama's Creations confirmed investor presentations. These are verified disclosures and filings issued Jan. 5–6, 2026. Based on 11 articles reviewed and supporting research.
More context
Timeline
- 1. Jan. 1, 2026 — Advanced Flower Capital's conversion to a BDC became effective.
- 2. Jan. 5, 2026 — Casella's CEO succession executed and multiple press releases published.
- 3. Jan. 5–6, 2026 — Companies declared monthly distributions and scheduled investor presentations.
- 4. Jan. 6, 2026 — Instil Bio subsidiary discontinued AXN-2510 and terminated the ImmuneOnco agreement.
- 5. Jan. 6, 2026 — Archrock announced intent to offer $500 million senior notes; Riot and TOMI issued operational updates.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
